(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Before trips to Mars, we need better protection from cosmic rays - 2The Best Computer games for Multiplayer Fun
- 3I tried a macho, creatine-loaded cereal “for men.” Did I mention I'm a woman?
- 4Asia's migrant workers debate if Gulf jobs are worth deadly risk of Iran war
- 5What to know about the hepatitis B shot — and why Trump officials are targeting it
- The 10 Most Famous Style Minutes on Honorary pathway
- Instructions to Investigate Different Open Record Extra Offers Actually
- The Land Rover Freelander Is Back—But It’s No Longer a Land Rover
- Which European palace do you fantasy about visiting? Vote!
- AI’s errors may be impossible to eliminate – what that means for its use in health care
- Could the Star of Bethlehem have actually been a comet?
- Shelby County deputies charged with assault, placed on leave
- Go on A Careful spending plan: Modest Objections for Your List of must-dos
- Vote In favor of Your #1 Electric Vehicles
